No abstract available
MeSH terms
-
Adalimumab
-
Adenocarcinoma / complications
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antitubercular Agents / therapeutic use
-
Ascites / etiology
-
Biological Products / adverse effects*
-
Biological Products / therapeutic use
-
Carcinoma / diagnosis
-
Carcinoma / secondary
-
Colorectal Neoplasms / complications
-
Diagnosis, Differential
-
Humans
-
Immunocompromised Host
-
Male
-
Middle Aged
-
Peritoneal Neoplasms / diagnosis
-
Peritoneal Neoplasms / secondary
-
Peritonitis, Tuberculous / diagnosis
-
Peritonitis, Tuberculous / drug therapy
-
Peritonitis, Tuberculous / etiology*
-
Spondylarthropathies / complications
-
Spondylarthropathies / drug therapy
-
Tuberculoma / diagnosis
-
Tuberculoma / drug therapy
-
Tuberculoma / etiology*
-
Tuberculosis, Pulmonary / complications
-
Tuberculosis, Pulmonary / drug therapy
Substances
-
Antibodies, Monoclonal, Humanized
-
Antitubercular Agents
-
Biological Products
-
Adalimumab